...NSCLC patients with previously untreated, EGFR mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21-day cycle) and erlotinib (at a dose of 150 mg once daily)...57 of the patients received at least once tumor assessment. 51 of them achieved partial response, 6 of them had stable disease and no patients had disease progression. The ORR was 89.5%, while the DCR was 100 %.